Navigation Links
Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC

CHICAGO, July 28, 2014 /PRNewswire-iReach/ -- June 28th, 2014 – Oncolab, the Boston-based laboratory which has developed the AMAS cancer test, is making its AACC debut (booth #4051) at this year's conference in Chicago.  To date, the test, which is a serum-based in vitro immunoassay, has been run for over 60,000 patients and is emerging as a significant tool in the fight against cancer recurrence.

Photo -

With an estimated 17 million cancer survivors in the US alone, the race is on to develop better technologies for identifying whether a cancer has begun to recur, and if so at what rate.  There is a clear trend towards the use of immunoassays in cancer diagnostics, as immunotherapy for treatment.  The AMAS test fits into these trends by measuring the level of a specific antibody, Anti-Malignin Antibody, which is thought to be produced by the body's immune system in response to nearly all forms of cancer.

Most other cancer immunoassays measure circulating levels of cancer antigens, which become elevated later than the antibody measured in the AMAS test.  As a result, the AMAS Test is an excellent aid to picking up recurrence at an early stage, since levels of anti-malignin antibody are often elevated early in the occurrence and recurrence of cancer.  This is a unique capability – false positive and false negative rates are under 10 percent.  While the AMAS Test does provide guidance as to the likely location of the cancer, new high-resolution imaging techniques such as MRI and CT, as well as more location-specific cancer tests, as well as clinical signs can help the clinician provide patients with the larger context.

Currently, Oncolab provides the test via submission of samples to its CLIA-certified laboratory in Boston, MA.  Serum samples must be shipped via overnight courier (FedEx, UPS or DHL) using a standardized shipping container and tubes provided at no cost by Oncolab, and dry ice obtained at the lab doing the blood draw and separation to serum.  The test is permitted to market by FDA, and reimbursed by Medicare.  Currently, the majority of samples being run are drawn in the US and Canada; overseas labs can also ship samples and are urged to contact Oncolab to get a technical and business relationship started.

The company is also working to develop a version of the test that can be run closer to the point of care; providers of new POC diagnostic platforms are encouraged to meet with the company's representatives at AACC to discuss possible development and deployment options.

Media Contact: Sarah Klein, Oncolab, Inc., 617-536-0850,

News distributed by PR Newswire iReach:

SOURCE Oncolab, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Talyst Exhibits at the National Association of State Veterans Homes Summer Conference
2. Varian Medical Systems Exhibits New Lightweight Wireless Flat-Panel Digital X-ray Image Detector for Imaging Extremities and for Neonatal Procedures
3. Varian Medical Systems Exhibits New Flat-Panel Digital X-ray Image Detectors Designed for High Energy Industrial and Security Applications
4. Kush Bottles Exhibits at Leading Industry Trade Show
5. BioDrain Medical Exhibits at National Registered Nurses Conference
6. Misonix Exhibits at Major Worldwide Spine Conference
7. Frost & Sullivan Applauds Check-Cap for Pioneering a Non-invasive, Prep-Free Wireless Capsule Endoscope
8. Pioneering Medical Device Patent Portfolio for Sale by ICAP Patent Brokerage
9. inVentiv Clinical Trial Recruitment Solutions Partners with Pioneering Firm to Revolutionize Clinical Trial Site Evaluation
10. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
11. inVentiv Health Partner Mytrus Inc. Wins Prestigious Award For Its Pioneering Technology In Electronic Informed Consent
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... Cell Therapy Catapult to advance development of large ... cell immunotherapy. Under the agreement, the Cell Therapy ... AST-VAC2 to support advanced clinical trials and eventual ... --> The Cell Therapy Catapult is ...
(Date:10/12/2015)... 13, 2015 the United States ... a non-clinical capacity. --> the United States ... a non-clinical capacity. --> The University of Texas MD ... the first high field (1.5 Tesla) MRI-guided linear accelerator in ... system will be operating in a non-clinical capacity. Royal ...
(Date:10/12/2015)... 2015 Given the intricacy of the ... to deliver an ophthalmic drug effectively to a specific ocular ... ocular drug delivery. These include dilution of a drug by ... conjunctiva and drug permeation issues with respect to the cornea, ... eye drops, is lost due to the aforementioned barriers. ...
Breaking Medicine Technology:
(Date:10/12/2015)... , ... October 12, 2015 , ... Advera Health ... no charge to qualified Managed Care Organizations (MCOs) in order to provide health plans, ... into their decision making process. In addition, the DSM is also being offered to ...
(Date:10/12/2015)... ... October 12, 2015 , ... To ... announced its charitable donation to the National Breast Cancer Foundation. The National Breast ... by breast cancer through early detection, education, and support services. , The annual ...
(Date:10/12/2015)... ... ... Clara dentist , Dr. Alan Frame, shares his insight on today’s dental hygiene and the ... “I want each one of my patients to be at their optimum level of health, ... implants dentist , Dr. Frame. He mentions, "As the white paper mentions, oral health care ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... receive a Eugene Washington Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) ... the research community. , The project, entitled “Training Patients with Asthma to ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... secured a new corporate headquarters, located at 485 Madison Avenue, New York, NY ... and increased emphasis on cloud-based technology. , “Care to Care is a dynamic ...
Breaking Medicine News(10 mins):